Wockhardt

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE049B01025
  • NSEID: WOCKPHARMA
  • BSEID: 532300
INR
2,086.95
16.15 (0.78%)
BSENSE

Sep 18, 03:30 PM

BSE+NSE Vol: 6.29 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Rubicon Research
Ipca Labs
Neuland Labs.
Gland Pharma
Ajanta Pharma
Emcure Pharma
Sai Life
Acutaas Chemical
Wockhardt
Glaxosmi. Pharma
Piramal Pharma

Why is Wockhardt Ltd ?

1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.42 times
  • Poor long term growth as Net Sales has grown by an annual rate of 3.72% over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.42 times
  • The company has been able to generate a Return on Equity (avg) of 1.21% signifying low profitability per unit of shareholders funds
2
Healthy long term growth as Operating profit has grown by an annual rate 44.88%
3
With a growth in Net Sales of 10.17%, the company declared Very Positive results in Jun 26
  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CF(Y) Highest at Rs 241.00 Cr
  • NET SALES(Latest six months) At Rs 1,894.00 cr has Grown at 27.89%
  • ROCE(HY) Highest at 7.47%
4
With ROCE of 6.5, it has a Very Expensive valuation with a 5.4 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 36.77%, its profits have risen by 1634.7% ; the PEG ratio of the company is 0.1
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Wockhardt should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Wockhardt for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Wockhardt
36.77%
0.70
52.29%
Sensex
-10.5%
-0.78
13.50%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
3.72%
EBIT Growth (5y)
44.88%
EBIT to Interest (avg)
0.41
Debt to EBITDA (avg)
22.57
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
0.49
Tax Ratio
10.58%
Dividend Payout Ratio
0
Pledged Shares
14.68%
Institutional Holding
16.48%
ROCE (avg)
0.01%
ROE (avg)
1.21%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
85
Industry P/E
37
Price to Book Value
6.85
EV to EBIT
64.85
EV to EBITDA
45.87
EV to Capital Employed
5.44
EV to Sales
9.94
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
6.53%
ROE (Latest)
6.07%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company
OPERATING CF(Y)

Highest at Rs 241.00 Cr

NET SALES(Latest six months)

At Rs 1,894.00 cr has Grown at 27.89%

ROCE(HY)

Highest at 7.47%

PBT LESS OI(Q)

At Rs 85.00 cr has Grown at 60.4% (vs previous 4Q average

PAT(Q)

At Rs 106.00 cr has Grown at 41.3% (vs previous 4Q average

DEBT-EQUITY RATIO(HY)

Lowest at 0.45 times

DEBTORS TURNOVER RATIO(HY)

Highest at 5.74 times

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Wockhardt

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 85.00 cr has Grown at 60.4% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 53.00 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 106.00 cr has Grown at 41.3% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 75.00 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Latest six months
At Rs 1,894.00 cr has Grown at 27.89%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Cash Flow - Annually
Highest at Rs 241.00 Cr
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Debt-Equity Ratio - Half Yearly
Lowest at 0.45 times
in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio- Half Yearly
Highest at 5.74 times
in the last five half yearly periods
MOJO Watch
Company has been able to settle its Debtors faster

Debtors Turnover Ratio